Pyrazine Derivatives for BRG1/BRM-Targeted BAF Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for disorders associated with alterations in BRG1 and BRM proteins, such as cancer, lack effective compounds that can modulate the BAF complex to regulate chromatin remodeling and impact gene expression.
Innovation Solution
Development of pyrazine derivatives that act as modulators of the BAF complex, specifically targeting BRG1 and BRM proteins, to treat disorders by altering their function and affecting chromatin remodeling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for disorders associated with BRG1 and BRM alterations, then existing therapeutic approaches are maintained, but effective modulation of BAF complex and chromatin remodeling is not achieved
Solution Approach 1:
The patent employs parameter changes by developing pyrazine derivative compounds with specific molecular structures (Formula I and II) that alter the biochemical parameters of BAF complex interaction. These compounds change the binding affinity and modulation efficacy parameters to achieve reliable treatment of disorders associated with BRG1 and BRM alterations.
2Reliability
If pyrazine derivatives are developed to modulate BAF complex, then effective treatment of disorders is achieved, but compound structure complexity increases
Solution Approach 1:
The pyrazine derivative compounds are segmented into distinct structural components defined in Formula I and II, including ring system A, substituents R1, linker L, and degradation moiety B. This segmentation allows for systematic optimization of therapeutic efficacy while managing molecular complexity through modular design.
Solution Approach 2:
The patent applies local quality by specifying particular structural features at different positions of the pyrazine core. Ring system A, linker L, and degradation moiety B each have specific structural requirements that optimize local interactions with BAF complex components, enhancing overall therapeutic efficacy without uniform complexity throughout the molecule.
Data Source
AI summary
The present disclosure features compounds Formula I or II: or pharmaceutically acceptable salts thereof, and formulations containing the same. Methods of treating BAF complex-related disorders, such as cancer, are also disclosed.